Literature DB >> 28987388

BMP4 promotes oxaliplatin resistance by an induction of epithelial-mesenchymal transition via MEK1/ERK/ELK1 signaling in hepatocellular carcinoma.

Junli Ma1, Shan Zeng2, Yan Zhang1, Ganlu Deng1, Yanling Qu1, Cao Guo3, Ling Yin1, Ying Han4, Changjing Cai2, Yiyi Li1, Guqi Wang5, Herbert L Bonkovsky6, Hong Shen7.   

Abstract

BACKGROUND: Bone morphogenetic protein-4 (BMP4) is a key regulator of epithelial-mesenchymal transition (EMT), which is crucial for cancer cells to acquire chemoresistance. The effects of BMP4 on OXA sensitivity in HCC need to be elucidated.
METHODS: Functional analysis of BMP4 on EMT-regulated OXA sensitivity was performed in human HCC specimens, in the HCC cell lines HepG2 and HCCLM3, and in a subcutaneous tumor model receiving OXA treatment. The downstream signaling targets of BMP4 in HCC were profiled and confirmed.
RESULTS: BMP4 expression was significantly increased in HCC tissue, and was correlated with tumor de-differentiation and unfavorable prognosis. BMP4 promoted HCC EMT and was correlated with OXA resistance. Blocking of BMP4 reversed EMT and increased OXA chemosensitivity in vitro and in vivo. ELK1, a transcription factor involved in EMT, was an important mediator of BMP4-induced OXA resistance in HCC. Blocking of MEK/ERK/ELK1 attenuated BMP4-induced EMT and enhanced OXA sensitivity.
CONCLUSIONS: BMP4 induces EMT and OXA chemoresistance via MEK/ERK/ELK1 signaling pathway in HCC. BMP4 may be a valuable therapeutic target for HCC patients receiving OXA-based chemotherapy.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bone morphogenetic protein 4; ELK1; Epithelial-mesenchymal transition; Hepatocellular carcinoma; Oxaliplatin

Mesh:

Substances:

Year:  2017        PMID: 28987388     DOI: 10.1016/j.canlet.2017.09.041

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  31 in total

1.  Bone morphogenetic protein 4 provides cancer-supportive phenotypes to liver fibroblasts in patients with hepatocellular carcinoma.

Authors:  Yohei Mano; Sachiyo Yoshio; Hirotaka Shoji; Shimagaki Tomonari; Yoshihiko Aoki; Nobuyoshi Aoyanagi; Toru Okamoto; Yoshiharu Matsuura; Yosuke Osawa; Kiminori Kimura; Kyohei Yugawa; Huanlin Wang; Yoshinao Oda; Tomoharu Yoshizumi; Yoshihiko Maehara; Tatsuya Kanto
Journal:  J Gastroenterol       Date:  2019-04-02       Impact factor: 7.527

2.  BMP4 augments the survival of hepatocellular carcinoma (HCC) cells under hypoxia and hypoglycemia conditions by promoting the glycolysis pathway.

Authors:  Jiamin Zhong; Quan Kang; Youde Cao; Baicheng He; Piao Zhao; Yannian Gou; Yetao Luo; Tong-Chuan He; Jiaming Fan
Journal:  Am J Cancer Res       Date:  2021-03-01       Impact factor: 6.166

3.  Expression of SLC22A18 regulates oxaliplatin resistance by modulating the ERK pathway in colorectal cancer.

Authors:  Tae Won Kim; Dae Hee Pyo; Eunbyeol Ko; Nak Hyeon Yun; Su Jeong Song; Soo Min Choi; Hye Kyung Hong; Seok-Hyung Kim; Yoon-La Choi; Jeeyun Lee; Woo Yong Lee; Yong Beom Cho
Journal:  Am J Cancer Res       Date:  2022-03-15       Impact factor: 6.166

4.  EGFR activates GDH1 transcription to promote glutamine metabolism through MEK/ERK/ELK1 pathway in glioblastoma.

Authors:  Rui Yang; Xiuxiu Li; Yanan Wu; Guanghui Zhang; Xiaoran Liu; Yanping Li; Yonghua Bao; Wancai Yang; Hongjuan Cui
Journal:  Oncogene       Date:  2020-02-07       Impact factor: 8.756

5.  Inhibition of pyruvate dehydrogenase kinase‑1 by dicoumarol enhances the sensitivity of hepatocellular carcinoma cells to oxaliplatin via metabolic reprogramming.

Authors:  Huadan Xu; Yichun He; Jiaoyan Ma; Yuanxin Zhao; Yanan Liu; Liankun Sun; Jing Su
Journal:  Int J Oncol       Date:  2020-07-10       Impact factor: 5.650

6.  MicroRNA-31-5p regulates chemosensitivity by preventing the nuclear location of PARP1 in hepatocellular carcinoma.

Authors:  Ke-Ting Que; Yun Zhou; Yu You; Zhen Zhang; Xiao-Ping Zhao; Jian-Ping Gong; Zuo-Jin Liu
Journal:  J Exp Clin Cancer Res       Date:  2018-11-06

7.  NOD-like receptor X1 functions as a tumor suppressor by inhibiting epithelial-mesenchymal transition and inducing aging in hepatocellular carcinoma cells.

Authors:  Bo Hu; Guang-Yu Ding; Pei-Yao Fu; Xiao-Dong Zhu; Yuan Ji; Guo-Ming Shi; Ying-Hao Shen; Jia-Bin Cai; Zhen Yang; Jian Zhou; Jia Fan; Hui-Chuan Sun; Ming Kuang; Cheng Huang
Journal:  J Hematol Oncol       Date:  2018-02-26       Impact factor: 17.388

8.  LncRNA NR2F1-AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR-363.

Authors:  Hai Huang; Jie Chen; Cheng-Ming Ding; Xin Jin; Ze-Ming Jia; Jian Peng
Journal:  J Cell Mol Med       Date:  2018-03-30       Impact factor: 5.310

9.  MicroRNA-125b reverses oxaliplatin resistance in hepatocellular carcinoma by negatively regulating EVA1A mediated autophagy.

Authors:  Wei-Wei Ren; Dan-Dan Li; Xiaolan Chen; Xiao-Long Li; Ya-Ping He; Le-Hang Guo; Lin-Na Liu; Li-Ping Sun; Xiao-Ping Zhang
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

10.  BMP4 promotes hepatocellular carcinoma proliferation by autophagy activation through JNK1-mediated Bcl-2 phosphorylation.

Authors:  Ganlu Deng; Shan Zeng; Yanling Qu; Qingqing Luo; Cao Guo; Ling Yin; Ying Han; Yiyi Li; Changjing Cai; Yaojie Fu; Hong Shen
Journal:  J Exp Clin Cancer Res       Date:  2018-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.